Laboratory Medicine and Pathology

Dr John W Macgregor Memorial Lecture

Dr. J.W. Macgregor
Chairman
Department of Pathology
 
1951 – 1970

The Dr. J. W. Macgregor Memorial Lecture is a tribute to Dr. Macgregor who was appointed as Chairman of the Department of Pathology in 1951 and held that position for 19 years until his retirement in 1970. Born in Winnipeg in 1905, he obtained his medical degree from the University of Alberta. He established a residency training program in General Pathology after World War II and was also the Provincial Pathologist. While he is remembered as a stern and demanding task master he was also generous and kind and became affectionately known as "Black Mac". After his retirement he continued to work until 1975 as Emeritus Professor.

___________________________________________________________________________________

2020 Dr. John W. Macgregor Memorial Lecture

   
Dr. Samuel Sia
Professor at Columbia University
Founder of Claros Diagnostics

 

 Title: TBD

 

Dr. Samuel Sia is a Professor at the Department of Biomedical Engineering at Columbia University. His lab's focuses on using microfluidics for global health diagnostics and for 3D tissue biology. He obtained his B.S in Biochemistry at the University of Alberta (Edmonton, Canada), Ph.D. in Biophysics at Harvard University, and postdoctoral fellowship in Chemistry at Harvard University. He was a Howard Hughes Medical Institute Predoctoral Fellow, National Science and Engineering Council of Canada Predoctoral Fellow, and Canadian Institute of Health Postdoctoral Fellow. Since 2005, he has been a faculty member of Columbia University's Biomedical Engineering department. His lab's work has been supported by the NIH, NSF, Wallace H. Coulter Foundation, American Heart Association, and World Health Organization. He has been named one of the world's top young innovators by MIT Technology Review, and one of 10 innovators in human health and sustainability by NASA. He is a founder of Claros Diagnostics, a venture capital-backed company that is developing novel point-of-care diagnostics products: the company's first microfluidics product for monitoring prostate cancer growth received European Union regulatory approval in 2010.